Monographs of Topical Drugs that Have Caused Contact Allergy/Allergic Contact Dermatitis
Anton C. de Groot in Monographs in Contact Allergy, 2021
Dimethindene is an indene histamine H1 antagonist. It is indicated as symptomatic treatment of allergic reactions such as urticaria, allergies of the upper respiratory tract such as hay fever and perennial rhinitis, and food and drug allergies. It is also used for pruritus of various origins, e.g. from insect bites, varicella, eczema and other pruriginous dermatoses on account of its sedative properties. In pharmaceutical products, dimethindene is employed as dimethindene maleate (CAS number 3614-69-5, EC number 222-789-2 [Dimetindene hydrogen maleate], molecular formula C24H28N2O4) (1).
Angioedema and anaphylaxis: Angioedema
Biju Vasudevan, Rajesh Verma in Dermatological Emergencies, 2019
The only H1 antihistamines given via IV application in the acute treatment of anaphylaxis are the first-generation substances dimetindene (0.1 mg/kg) and clemastine (0.05 mg/kg). Second-generation antihistamines can be used in severe and treatment-resistant anaphylaxis orally.
Analytical investigation of ternary mixture of phenylephrine hydrochloride, dimetindene maleate and benzalkonium chloride using validated stability indicating HPLC-DAD method
Published in Drug Development and Industrial Pharmacy, 2020
Ahmed G. Abdelhamid, Dina S. El-Kafrawy, Magdi M. Abdel-Khalek, Tarek S. Belal
There are many nonprescription (over-the-counter; OTC) medications available on pharmacy shelves marketed for relief of respiratory symptoms. Different combinations of antihistamines and decongestants along with other active ingredients have been widely used in OTC medications taken by adults and children for upper respiratory illnesses such as allergic rhinitis and common cold [1,2]. Nasal preparations containing the direct sympathomimetic agent phenylephrine HCl (PHR) and the highly potent H1 antagonist dimetindene maleate (DMD) are commonly used to relief nasal congestion caused by various conditions including common cold, sinusitis and allergies. These pharmaceutical formulations contain benzalkonium chloride (BZM) as preservative to maintain the microbiological quality of the dosage forms. Chemical structures of the three drugs are shown in Figure 1.
Drug-induced Stevens-Johnson syndrome: a disproportionality analysis from the pharmacovigilance database of the World Health Organization
Published in Expert Opinion on Drug Safety, 2022
Yi Zheng, Wenli Zhou, Xiaojing Guo, Lijie Chi, Chenxin Chen, Zhijian Guo, Jizhou Liang, Lianhui Wei, Xiao Chen, Xiaofei Ye, Jia He
The five drugs with the strongest IC025 signals were allopurinol (IC025/ROR025 = 5.86/69.84), phenytoin (IC025/ROR025 = 5.60/57.65), carbamazepine (IC025/ROR025 = 5.25/43.88), nevirapine (IC025/ROR025 = 5.13/38.91), and lamotrigine (IC025/ROR025 = 4.84/32.26). In the top strongest 30 signals, cefcapene (IC025/ROR025 = 4.02/21.74, N = 49), garenoxacin (IC025/ROR025 = 3.76/19.56, N = 35), carbocisteine (IC025/ROR025 = 3.56/13.62, N = 69), dimetindene (IC025/ROR025 = 3.55/22.16, N = 21) and piritramide (IC025/ROR025 = 3.29/32.35, N = 13) were the 5 drugs had no cases reported on PubMed. We then searched these drugs in FDA label and EMC label, among them, only piritramide’s FDA label suggested that it can caused SJS. Cefcapene and garenoxacin were first licensed in Japan, cefcapene had been proved in its Japanese label, garenoxacin had not. Carbocisteine was first licensed in Holland, which was one kind of antibiotic, and carbocisteine is one of the most commonly used expectorant drugs, which need to pay more attention when used for patients. Dimetindene was licensed in England, which was used to against skin allergies, which is one of the antihistamines drugs. Although these 3 drugs didn’t have the SJS in their labels’ adverse event and have not had widespread use, they were detected to be strongly associated SJS, which are several high-risk drugs that need more attention. Further study should focus on these drugs to verify the causal association between the drug and the SJS, if were identified, the MAH/Regulatory need to be warranted.
Clinical features of angioedema induced by renin-angiotensin-aldosterone system inhibition: a retrospective analysis of 84 patients
Published in Journal of Community Hospital Internal Medicine Perspectives, 2019
Anja Pfaue, Patrick J. Schuler, Benjamin Mayer, Thomas K. Hoffmann, Jens Greve, Janina Hahn
In 71 patients with RAE (85%), the therapy consisted of corticosteroids (mostly Prednisolone-21-hydrogensuccinate, Solu-Decortin®H 250–500 mg i.v.), antihistamines (in most cases, Dimetindene 4 mg and Ranitidine 50 mg i.v.), and inhaled Epinephrine. This treatment complies with the standard anti-allergic therapeutic concept of the department. Eleven patients (13%) were treated with C1 INH i.v. or the bradykinin 2 receptor blocker Icatibant s.c. in addition to the anti-allergic medication.
Related Knowledge Centers
- Allergic Rhinitis
- Anticholinergic
- Antipruritic
- Antihistamine
- H1 Antagonist
- Blood–Brain Barrier
- Pharmaceutical Formulation
- Maleic Acid
- Salt